Clinical Isolate Core (Core B)

临床分离核心（核心 B）

• 批准号: 10583499
• 负责人: Jesse Thomas Jacob
• 金额: $ 36.8万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-05 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10583499
• 关键词: Acinetobacter; Acinetobacter baumannii; Age; Antibiotic Resistance; Antibiotics; Area; Blood Circulation; Board Certification; Centers for Disease Control and Prevention (U.S.); Characteristics; Clinical; Clinical Microbiology; Collection; Communicable Diseases; Complex; Data; Descriptive Epidemiology; Enterobacter; Enterobacteriaceae; Epidemiologist; Epidemiology; Escherichia; Funding; Genetic; Genotype; Goals; Healthcare; Infection; Interdisciplinary Study; Intermediate resistance; Klebsiella; Knowledge; Laboratories; Leadership; Link; Medical; Medical Device; Metabolic; Methodology; Methods; Patient Care; Pattern; Population Analysis; Predisposition; Prevalence; Process; Publications; Race; Reproducibility; Research; Research Project Grants; Risk Factors; Scientist; Site; Standardization; Sweden; Syndrome; Testing; Universities; University Hospitals; Urine; Work; biobank; carbapenem resistance; longitudinal analysis; multi-drug resistant pathogen; multidisciplinary; novel; operation; population based; programs; prospective; prospective test; respiratory; sex; statistics; success; trend

PROJECT SUMMARY/ABSTRACT The overall objective of the Clinical Isolate Core (Core B) is to provide access to a robust collection of clinical bacterial isolates and a standardized and experimentally controlled platform for evaluating antibiotic heteroresistance (HR) for the Heteroresistance Interdisciplinary Research Unit (HR-IRU). Core B is therefore essential to the overall success of the HR-IRU program. To accomplish Core goals, we have assembled a multidisciplinary team including an infectious disease clinician (Jacob), a research scientist (Satola), a board- certified medical microbiologist (Burd) and an epidemiologist (Tunali) with expertise vast areas of antibiotic resistance. For Core B to enable successful completion of the research projects and advance our understanding of antibiotic HR we propose three specific aims. 1) To provide access to clinical bacterial isolate. Isolates (Enterobacterales and Acinetobacter baumanii complex) will be collected as part of the Centers for Disease Control and Prevention's (CDC) Georgia Emerging Infections Program (EIP) Multi-site Gram-negative Surveillance Initiative (MuGSI), Emory University's Investigational Clinical Microbiology Core (ICMC) biorepository, and Uppsala University Hospital, Sweden. 2) To profile clinical bacterial isolates for HR. We will test 500 bacterial isolates per year from bloodstream, urine, and respiratory clinical infections: 200 multi-drug resistant organisms (MDRO) from the Georgia EIP; 100 non-MDRO from the ICMC and 200 predominately susceptible isolates from Uppsala University Hospital, Sweden. Each isolate will be tested for HR to approximately 20 antibiotics using population analysis profiling (PAP), the gold standard for HR. 3) To perform epidemiological analyses revealing the prevalence, type and trends of HR. We will establish the prevalence of HR from the 2500 isolates tested in aim 2. We will perform comprehensive descriptive epidemiology on the clinical and laboratory characteristics of isolates with HR and compare those to isolates without HR. Core B will be conducted in the laboratories of the Georgia EIP and Emory University's ICMC, which have extensive expertise in active-population based surveillance and studies of HR. The Core leadership will work closely with the HR-IRU program directors/PIs and project leaders to ensure that the needs of all projects are rigorously met in a reliable, reproducible and timely manner.

项目概要/摘要 临床隔离核心（核心 B）的总体目标是提供对临床隔离核心的强大集合的访问 细菌分离株和用于评估抗生素的标准化和实验控制平台 异质抗性（HR）为异质抗性跨学科研究单位（HR-IRU）。因此核心B是 对于 HR-IRU 计划的整体成功至关重要。为了实现核心目标，我们组建了 多学科团队，包括一名传染病临床医生（Jacob）、一名研究科学家（Satola）、一名董事会成员 经过认证的医学微生物学家 (Burd) 和流行病学家 (Tunali)，拥有抗生素广泛领域的专业知识 反抗。核心 B 能够成功完成研究项目并增进我们的理解 对于抗生素 HR，我们提出了三个具体目标。 1) 提供临床细菌分离株。分离物 （肠杆菌和鲍曼不动杆菌复合体）将作为疾病中心的一部分收集 控制与预防 (CDC) 佐治亚州新发感染计划 (EIP) 多站点革兰氏阴性菌 监测倡议 (MuGSI)、埃默里大学临床微生物学研究核心 (ICMC) 生物样本库和瑞典乌普萨拉大学医院。 2) 分析 HR 的临床细菌分离株。我们将 每年测试 500 种从血液、尿液和呼吸道临床感染中分离出来的细菌：200 种多种药物 来自佐治亚州 EIP 的抗药性生物体 (MDRO)；来自 ICMC 的 100 个非 MDRO 和 200 个主要 来自瑞典乌普萨拉大学医院的敏感菌株。每个分离株都将进行 HR 测试，以 使用群体分析分析 (PAP)（HR 的黄金标准）分析大约 20 种抗生素。 3）执行 流行病学分析揭示 HR 的患病率、类型和趋势。我们将确定流行率 目标 2 中测试的 2500 个分离株的 HR。我们将对目标进行全面的描述性流行病学研究 具有 HR 的分离株的临床和实验室特征，并将其与无 HR 的分离株进行比较。核心B将 在乔治亚州 EIP 和埃默里大学 ICMC 的实验室中进行，这些实验室拥有广泛的 基于活跃人群的人力资源监测和研究方面的专业知识。核心领导层将与 HR-IRU 项目主管/PI 和项目负责人确保严格满足所有项目的需求 以可靠、可重复和及时的方式。